Investigational Treatment for Dementia Associated with Parkinson’s Disease
SYN-120 is currently in Phase 2 development by our Biotie Therapies subsidiary (acquired in 2016) for treatment of Parkinson’s disease (PD)-related dementia. Dementia is a physical change in the brain that causes a decline in the brain’s ability to process and understand information, an can affect thinking, perception, and mood.
You can learn more about the SYN120 trial, including how to participate in the study, here. This study has received funding from the Michael J. Fox Foundation. It is expected to be completed in the first half of 2018.
According to recent studies following people with Parkinson’s disease over the entire course of their illness, approximately 50-80% may experience dementia. Some studies have reported that the average time from onset of Parkinson’s disease to developing dementia is about 10 years.
As Parkinson’s progresses over time, PD-related dementia can cause problems with:
• Memory loss and forgetfulness
• Speaking and communicating with others
• Problem solving and understanding of complex ideas
• Paying attention
• Emotional control, mood, and motivation
• Confusion, anxiety, and hallucinations
SYN-120 is an investigational oral 5-HT6/5-HT2A dual receptor antagonist, a mechanism of action that has shown promise for the symptomatic treatment of PD-related dementia, as well as other conditions, including Alzheimer’s dementia.